NEW YORK, May 3, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Delcath Systems, Inc. ("Delcath" or the "Company") (NasdaqCM: DCTH). The investigation focuses on whether the Company and its executives violated federal securities laws.
On May 2, 2013, shares of the Company plunged in after hour trading after an FDA Advisory Committee voted 16-0 against recommending the company's Melblez kit therapy for treatment of hepatic-dominant metastatic ocular melanoma. In the FDA staff briefing released on Tuesday, reviewers noted that "substantial and severe toxicity" was identified in the clinical trials, with seven percent of the 122 patients treated by the drug-device combination dying as a result of treatment related side effects. The company failed to disclose all these risks and other material issues in its Phase 3 trials to investors. DCTH shares have fallen $.99 to $.40 (-71%) since the time the FDA Advisory Committee disclosed its briefing documents and ultimately held its vote.
If you are aware of any facts relating to this investigation, or purchased shares of Delcath, you can assist this investigation by contacting Peretz Bronstein of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC